Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adjuvant, Allan, Allegheny, amdizalisib, anesthesiologist, anesthesiology, answer, Appendix, arena, Ashland, Atkin, axatilimab, Baring, Biosecurity, bispecific, Black, Booth, break, bridging, broadly, broker, Bulletin, buyout, CAC, campaign, CaoJN, carboplatin, CBR, censorship, CgA, Chen, Chicago, Chig, chose, Circle, cisplatin, collusion, Computershare, concept, confirmatory, Conjugate, consolidatedfinancial, consummated, CR, cure, Cyberspace, cytoplasmic, Daiichi, demographic, dental, destroyed, deter, dialogue, disagreement, dissolved, divestiture, DLT, Edition, elzovantinib, emactuzumab, EMBA, endorsed, energy, epithelioid, Epizyme, evobrutinib, exact, Faculty, female, fenebrutinib, Folfiri, forecast, forfeiture, forgery, fruquintnib, Fung, Gazyva, GDP, gearing, gemcitabine, George, giant, GL, hemolytic, hereunder, heterobifunctional, HFCAA, HHOHK, histone, HKCGI, HKEX, homolog, Hung, hyperactivate, Hyperglycemia, ID, IDHm, IIIb, improper, incentivize, intensified, intervene, involuntarily, IO, Jagiellonian, Jane, Jean, Kam, Kania, Katowice, Kazia, Keung, Kin, Krakow, Krzysztof, lawrence, leaked, lenalidomide, Lunit, lysine, macroeconomic, MAH, maliciously, Marek, mathematical, matrix, MDS, MEK, Middlesex, mismatch, mitochondrial, moratorium, Mountrose, myelodysplastic, myeloproliferative, Nanjing, NDRL, Nemtabrutinib, neuroscience, Nixon, nongenetic, NY, ORCHARD, orelabrutinib, override, Pachytene, palliative, peculiar, perpendicular, phone, pirtobruntinib, PLA, pMMR, Poland, pos, postponed, Pricewaterhouse, PricewaterhouseCooper, Prime, processor, proficient, prominent, proof, prorated, PTCL, Qingmei, quantifying, realistic, remibrutinib, renovation, repossession, repsectively, Republican, resection, reward, rewarded, Rigel, rilzabrutinib, rituximab, Rupert, Rutherford, SACHI, SAFFRON, salary, SAMETA, Sankyo, SANOVO, Save, SEHK, shortest, Silesian, skepticism, societal, sovleplenib, SPD, stemming, subset, supervisory, surface, surgical, synergize, Tabrecta, tazemetostat, Tazemetotat, Tazverik, tenosynovial, TGCT, thirteen, timeframe, today, tolebrutinib, transcription, Trillium, Truseltiq, TTR, Turalio, unmanaged, unresearchable, urothelial, vacated, Vall, VectivBio, vimseltinib, wAIHA, warm, WCLC, wholesaling, Yang, Yu, zeste
Removed:
absorbed, additive, advertise, Africa, ago, alongside, altered, Anhui, archived, aspect, assured, ASU, atopic, axial, axl, Baiyao, baricitinib, border, Bowel, BSC, buyer, capita, Capsule, channel, Chile, Comprehensively, creditworthy, Crohn, CSRC, Da, Danshen, deem, deletion, differentiate, diligently, disposable, Dropping, element, emerged, encouragingly, entrusted, EORTC, ESPN, explained, FGF, filgotinib, fluctuated, futility, gamma, genolimzumab, Genome, geographical, Gilotrif, glial, GU, HCML, Heilongjiang, hereinafter, HHOL, histologically, HMP, HMPHK, HMPL, hongkong, inactive, infigratinib, Iressa, JAK, Jakafi, Johnson, Keytruda, Lai, LeiYunShang, library, licensor, Luo, lymph, Malaysia, maximize, Merck, Merestinib, MERTK, Mexico, modest, Nestec, NHS, nodal, node, NSPL, Olumiant, optional, orthotopic, periodical, Peru, pharmacologically, positioning, pressure, problem, prodrug, propose, psoriatic, quetiapine, ranging, rapamycin, recognizing, repaid, repaying, retrospectively, risky, rotating, ruxolitinib, SAVOIR, score, Scotiabank, separated, sequencing, Shan, sharp, Shijiazhuang, slowdown, substitute, succeeded, supplying, Surcharge, Tabular, Tannir, Tasly, TBD, TEK, TM, tofacitinib, Tongrentang, Tou, Ukraine, ulcerative, unchanged, understand, untested, upadacitinib, VAT, wholesale, Xeljanz, Xiangxue, Yiling, Yun, Yunnan
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 1.1 Exhibit 1.1
- 2.4 Exhibit 2.4
- 4.2 Exhibit 4.2
- 4.15 Exhibit 4.15
- 4.16 Exhibit 4.16
- 4.17 Exhibit 4.17
- 8.1 Exhibit 8.1
- 12.1 Exhibit 12.1
- 12.2 Exhibit 12.2
- 13.1 Exhibit 13.1
- 13.2 Exhibit 13.2
- 15.1 Exhibit 15.1
- 15.2 Exhibit 15.2
- 15.3 Exhibit 15.3
- 15.4 Exhibit 15.4
- 15.5 Exhibit 15.5
- Download Excel data file
- View Excel data file
HCM similar filings
Filing view
External links
Exhibit 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-240180, No. 333-224391 and No.333-212406) and Form F-3 (No. 333-237574) of HUTCHMED (China) Limited (formerly known as “Hutchison China MediTech Limited”) of our report dated March 3, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F.
| | |
/s/ PricewaterhouseCoopers Zhong Tian LLP | | |
Shenzhen, the People’s Republic of China | | |
March 3, 2022 | |